---
title: "Kepler Capital  Keeps Their Buy Rating on Corbion NV (0QHL)"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/277271231.md"
description: "Kepler Capital analyst Karel Zoete has maintained a Buy rating on Corbion NV (0QHL) with a price target of €31.00, while the shares closed at €20.50. The analyst has a 0.5% average return and a 56.35% success rate, covering the Consumer Defensive sector. The current consensus on Corbion NV is a Hold, with an average price target of €19.60."
datetime: "2026-02-28T01:55:00.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/277271231.md)
  - [en](https://longbridge.com/en/news/277271231.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/277271231.md)
---

# Kepler Capital  Keeps Their Buy Rating on Corbion NV (0QHL)

In a report released on February 26, Karel Zoete from Kepler Capital maintained a Buy rating on Corbion NV, with a price target of €31.00. The company’s shares closed last Thursday at €20.50.

### Claim 50% Off TipRanks Premium

-   Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
-   Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential

According to TipRanks, Zoete is a 2-star analyst with an average return of 0.5% and a 56.35% success rate. Zoete covers the Consumer Defensive sector, focusing on stocks such as Unilever, Ontex Group N.V., and Sligro Food Group NV.

Currently, the analyst consensus on Corbion NV is a Hold with an average price target of €19.60.

### Related Stocks

- [CVAC.US](https://longbridge.com/en/quote/CVAC.US.md)

## Related News & Research

- [Why This Analyst Thinks Texas Instruments Stock Is on the Path to $1 Trillion](https://longbridge.com/en/news/286957345.md)
- [LifeSci Capital Sticks to Their Buy Rating for Olema Pharmaceuticals (OLMA)](https://longbridge.com/en/news/286679129.md)
- [Analyst Reiterates Buy on Dermata, Keeps 12-Month Price Target Unchanged at $4](https://longbridge.com/en/news/286958909.md)
- [Q2 EPS Forecast for Avalo Therapeutics Boosted by Analyst](https://longbridge.com/en/news/286903837.md)
- [Earnings Beat: Deepak Nitrite Limited Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Models](https://longbridge.com/en/news/286980047.md)